Involvement of phosphatidylcholine-selective phospholipase C in activation of mitogen-activated protein kinase pathways in imidazoline receptor antisera-selected protein.
Imidazoline receptor antisera-selected protein (IRAS) is considered as a candidate for the I1-imidazoline receptor (I1R), but the signaling pathway mediated by IRAS remains unknown. In our study, the signal transduction pathways of IRAS were investigated in CHO cells stably expressing IRAS (CHO-IRAS), and compared to the native I1R signaling pathways. Rilmenidine or moxonidine (10 nM-100 microM), I1R agonists, failed to stimulate [35S]-GTPgammaS binding in CHO-IRAS cell membrane preparations, suggesting that G protein may not be involved in IRAS signaling pathway. However, incubation of CHO-IRAS with rilmenidine or moxonidine for 5 min could induce an upregulation of phosphatidylcholine-selective phospholipase C (PC-PLC) activity, and an increase in the accumulation of diacylglycerol (DAG), the hydrolysate of PC-PLC, in a concentration-dependent manner. The elevated activation of PC-PLC by rilmenidine or moxonidine (100 nM) could be blocked by efaroxan, a selective I1R antagonist. Cells treated with rilmenidine or moxonidine showed an increased level of extracellular signal-regulated kinase (ERK) phosphorylation in a concentration-dependent manner, which could be reversed by efaroxan or D609, a selective PC-PLC inhibitor. These results suggest that the signaling pathway of IRAS in response to I1R agonists coupled with the activation of PC-PLC and its downstream signal transduction molecule, ERK. These findings are similar to those in the signaling pathways of native I1R, providing some new evidence for the relationship between I1R and IRAS.
Li
Fei
F
Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Wu
Ning
N
Su
Rui-Bin
RB
Zheng
Jian-Quan
JQ
Xu
Bo
B
Lu
Xin-Qiang
XQ
Cong
Bin
B
Li
Jin
J
D000818:Animals; D016466:CHO Cells; D002462:Cell Membrane / Q000378:metabolism; D006224:Cricetinae; D004075:Diglycerides / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D006160:Guanosine Triphosphate / Q000378:metabolism; D007093:Imidazoles / Q000494:pharmacology; D054755:Imidazoline Receptors; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism*; D008024:Ligands; D020935:MAP Kinase Signaling System; D010080:Oxazoles / Q000494:pharmacology; D000077769:Rilmenidine; D015398:Signal Transduction; D010738:Type C Phospholipases / Q000378:metabolism*
D004075:Diglycerides; D007093:Imidazoles; D054755:Imidazoline Receptors; D047908:Intracellular Signaling Peptides and Proteins; D008024:Ligands; C458505:NISCH protein, human; D010080:Oxazoles; D006160:Guanosine Triphosphate; C043482:moxonidine; D048049:Extracellular Signal-Regulated MAP Kinases; D010738:Type C Phospholipases; C105598:phosphatidylcholine-specific phospholipase C; D000077769:Rilmenidine